$ADHD to Participate at Two Conferences in May


Alcobra Ltd. to Participate at Two Conferences in May

 Alcobra Ltd. (ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced participation at two conferences in May.

Deutsche Bank 40th Annual Health Care Conference
Date: Wednesday May 6
Location: Intercontinental Hotel, Boston
Company Representative: Dr. Yaron Daniely, President & CEO
IATI Biomed 2015
Date: Wednesday May 13
Location: Tel Aviv Convention Center
Company Representative: Dr. Tomer Berkovitz, CFO

About Alcobra Ltd.

Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and Fragile X Syndrome. MDX has completed multiple Phase II studies in adults and adolescents with ADHD and has completed a Phase III study in adults with ADHD. The company is conducting a Phase II trial in adolescents and adults with Fragile X Syndrome. For more information please visit the Company’s website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.

U.S. Investor Contacts
LifeSci Advisors, LLC
Michael Rice
[email protected]com
Media Inquiries
Sam Brown, Inc.
Mike Beyer
[email protected]
Israel Investor Contact:
Alcobra Investor Relations
Debbie Kaye
+972-72 2204661
[email protected]


Please enter your comment!
Please enter your name here